INTRODUCTION {#s1}
============

Cancer is the most important reason for death globally, and the cancer-related morbidity and mortality rate is anticipated to increase over the next couple years. On the basis of the WHO (World Health Organization), if the total cancer incidence remains relatively constant, by 2030, the number of new cancer cases will more than doubled to today \[[@R1]\]. Irreparable structural mutations in cells are the main cause of human cancer. These mutations can alter the DNA copy number and function of the gene at very specific genomic locations \[[@R2], [@R3]\]. Pollack et al. established that CNAs uncover all gene expression, which could be a critical element in the tumor development \[[@R4]\]. Identifying copy number alterations can state a method for linking CNA with disease phenotype \[[@R5]\]. This study can provide theoretical basis for clinicians and researchers, and finds out a new signaling pathway or biomarker in cancer which is helpful to develop the therapeutic approach for early intervention in preventing cancer.

Cell proliferation and elevated invasiveness are the two most prominent hallmarks of cancer cells that result in the majority of cancer patients' deaths \[[@R6]\]. The actin cytoskeleton is essential for many cellular functions including cell migration. Several pieces of evidence have shown that the actin-regulating protein is involving in the cell motility and invasiveness of human cancers. Adenylate cyclase-associated protein (CAP) is one of the major actin-regulating proteins in cancers.

CAP was first found in yeast. It is an actin monomer-binding protein coded by the *CAP* gene and has been observed to involve in cell motility and progress of particular kinds of cancers. The two isoforms of CAPs identified in mammals are CAP1 and 2. CAP1 exists in almost all tissues and cells, But, CAP2 is expressed in specific tissues and cells. Recent studies, including those from our group, have established that mammalian CAP1 is overexpressed in NSCLC tissues and correlated with poor clinical outcomes \[[@R7]\]. On the other hand, CAP2 has been found to be overexpressed in melanoma and hepatocellular carcinoma \[[@R8]--[@R9]\]. Knockdown of CAP1 leads to reduced cell motility in lung and pancreatic cancer \[[@R7], [@R10]\]. However, depletion of CAP1 in HeLa cells and breast cancer cells substantially stimulates the migration and invasion \[[@R11], [@R12]\]. These results indicate that CAP may either play oncogenic or anti-oncogenic function hinging on cancer types. Nevertheless, the exact role of CAP expression remains elusive and controversial based on the conflicting evidence.

To explore the character of CAP members in cancers, Oncomine platform assesses the gene expression of cancers by nearly 90,000 microarray experiments (<http://www.oncomine.com>) \[[@R13], [@R14]\]. Furthermore, the survival of cancer patients was assessed by Kaplan-Meier plotter and PrognoScan database \[[@R15], [@R16]\]. The co-expression data revealed the biological function and provided insight into the potential underlying mechanism. The gene ontology enrichment by STRING (<http://string-db.org>) is able to discover the function and regulatory mechanism of genes \[[@R17], [@R18]\]. The present aimed to determine if the CNAs of the CAP axis correlated with aggressive cancer sub-types, based on the cBioPortal and Tumorscape \[[@R19]--[@R22]\] (Table [1](#T1){ref-type="table"}). The first study showing the role of CAP in cancers. Therefore, detailed analyses of CAP1 and CAP2 have been described below.

###### Main characteristic of the selected oncogenomic portals

  database                   Data source                                                                                                                                                                                                  Sites of analyzed cancer 1                                                                                                                   Oncogenomic data                                                                                                                                                                                                                   link
  -------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ -------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------
  **Oncomine**               TCGA, Cancer data from literature                                                                                                                                                                            Bd; Br; Bra; Cer; Clr; Eso; HN; Kd; Lng; Lvr; Lymph; Ov; Pnc; also: cancer cell lines                                                        Drug Sensitivity, Cancer histology, clinical outcome, tissue, pathology, subtype, molecular subtype, patient treatment response                                                                                                    <https://www.oncomine.org> \[[@R13], [@R14]\]
  **Kaplan-Meier plotter**   Cancer data from literature                                                                                                                                                                                  Br, Ov; Lng; GIST;                                                                                                                           survival analyses                                                                                                                                                                                                                  <http://kmplot.com/analysis> \[[@R15]\]
  **Prognoscan**             Cancer data from literature                                                                                                                                                                                  Bd; Bld; Br; Bra; Clr; EA; Eso; HN; Kd; Lng; Lymph; Ov; Prst; Sk; ST;                                                                        survival analyses                                                                                                                                                                                                                  <http://www.abren.net/PrognoScan/>\[[@R16]\]
  **STRING**                 Protein, gene from literature                                                                                                                                                                                Gene, gene from literature                                                                                                                   Structure                                                                                                                                                                                                                          <http://string-db.org> \[[@R17], [@R18]\]
  **cBioPortal**             AMC, BCCRC, BGI, British Columbia, Broad, Broad/ Cornell, CCLE, CLCGP, Genentech, ICGC, JHU, Michigan, MKSCC, MKSCC/ Broad, NCCS, NUS, PCGP, Pfizer UHK, Riken, Sanger, Singapore, TCGA, TSP, UTokyo, Yale   ACC; Bd; Bld; Br; Bra; Chl; Clr; Eso; HN; Kd; Lng; Lvr; Lymph; MM; Npx; Ov; Pnc; Prst; Sk; ST; Stc; Thr; Utr; also: cancer cell lines        mutations, putative copy number alterations; mRNA expression, protein/ phosphoprotein level; survival analyses                                                                                                                     <http://www.cbioportal.org/> \[[@R19], [@R20]\]
  **Tumorscape**             Broad Institute                                                                                                                                                                                              Bd; Bld; Br; Bra; Clr; Eso; GIST; HN; Htp; Kd; Lng; Lvr; Lymph; Msh; Ov; Pnc; Prst; Sk; ST; Stc; Swn; Thr; Utr; also in: cancer cell lines   copy number alterations                                                                                                                                                                                                            <http://www.broadinstitute.org/tumorscape/> \[[@R21], [@R22]\]
  **ICGC**                   ICGC, TCGA, TARGET                                                                                                                                                                                           ACC; Bd; Bld; Br; Bra; Chl; Clr; Eso; HN; Kd; Lng; Lvr; Lymph; MM; Npx; Ov; Pnc; Prst; Sk; ST; Stc; Thr; Utr; also: cancer cell lines        simple somatic mutations, copy number somatic alterations, structural somatic mutations, simple germline variants, DNA methylation, gene/ protein expression, miRNA expression, exon junction; epidemiological and clinical data   <https://dcc.icgc.org>.\[[@R73], [@R74]\]

1 List of abbrieviations of cancer sites. In the brackets there are exemplary cancer subtypes included in the portals. ACC -- adenoid cystic carcinoma; Bd -- bladder; Bld -- blood; Bo -- bone; Br -- breast; Bra -- brain; Chl -- cholangiocarcinoma; Clr -- colorectal; Col -- colon; EA -- eye and adnexa; EG - endocrine glands; Eso -- esophagus; GIST -- gastrointestinal; HN -- head and neck; Htp -- hematopoietic; Kd -- kidney; Lng -- lung; Lvr -- liver and biliary tract; Lymph -- Lymphoma; Msh -- mesothelioma; Mth -- mouth; Nb -- neuroblastoma; Npx -- nasopharynx; Ov -- ovary; Pan -- pancancer; Pnc -- pancreas; Pnx -- pharynx; Prc/Prn - pheochromocytoma and paraganglioma; Prst -- prostate; Rc -- rectum; Sk -- skin; ST -- soft tissues; Stc -- stomach; Swn -- schwannoma; Thm -- thymus; Thr -- thyroid; Tst -- testis; Utr -- uterine (cerxix and corpus).

CAP1 may play a potential oncogenic role in pancreatic cancer and tumor suppressor in breast cancer. Also, the relationship between CAP1 expression levels and patient survival was observed. The co-expression analysis revealed that CAP1 was coexpressed with TUBA1B in pancreatic and head-neck cancer, as well as with CFL1, CFL2, DSTN, ACTB, ACTG1, and ROBO1, according to the STRING analysis. High CAP2 expression showed a relatively good prognosis in breast cancer, whereas poor prognosis in gastric and ovarian cancers. CAP2 was coexpressed with TP53BP2 and ENA/VASP in liver cancer. The cBioPortal and Tumorscape analysis found that frequency of 40.2--20% with the rank order mainly in prostate cancer with CAP1, CAP2 alteration ranged from 38.3--19.8%. The CAP mutations occur in a hotspot in the CAP N domain. Totally, the different subtype of CAP is involves in different cancer types. CAP-coexpressed molecules may be established further to elucidate the function of CAP members in the specific type of cancer. Together, these results provide additional support for CAP as a biomarker and a target for cancer therapy.

RESULTS {#s3}
=======

To explore the role of CAP in cancers. The expression of CAP was analyzed between tumor and normal tissues using the Oncomine database. The threshold was designated according to the following values: *p*-value 1E-4, fold change 2, and top gene ranks 10%. The CAP was over-expressed in certain types of cancers and lower in others as compared to that of the normal tissue. These results indicate that CAP may work either oncogenic or anti-oncogenic function according to the cancer types (Figure [1](#F1){ref-type="fig"}). Thus, detailed analyses of CAP1 and CAP2 were described below.

![CAP mRNA expression in various cancer types\
The comparison indicated the number of datasets with CAP mRNA overexpression (right column, red) and under expression (left column, blue) in cancer versus normal tissue. The threshold was designed with following parameters: *p*-value of 1E-4, fold change of 2, and gene ranking of 10%.](oncotarget-08-27216-g001){#F1}

CAP transcript expression by cancer type {#s3_1}
----------------------------------------

CAP has been shown as an actin-regulatory protein. Mammals harbor two CAP isoforms, CAP1 and CAP2 \[[@R23], [@R24]\]. Depletion of CAP1 reduces actin dynamics, cell motility and cell invasion \[[@R11], [@R23], [@R24]\]. Our analysis revealed that CAP1 was over-expressed in bladder, lung, lymphoma, melanoma, head-neck, pancreatic cancers, but was under-expressed in breast and leukemia cancers as compared to that in normal tissue (Table [2](#T2){ref-type="table"}, Figure [2](#F2){ref-type="fig"}, [Supplementary Figures 1--3](#SD1){ref-type="supplementary-material"}) \[[@R25]--[@R39]\]. These data are in agreement with the previously published reports on CAP1 expression. For instance, our study indicated that CAP1 is highly expressed in lung cancer \[[@R7]\] ([Supplementary Figure 1B](#SD1){ref-type="supplementary-material"}), elevated in pancreatic cancer \[[@R10]\] (Figure [2C](#F2){ref-type="fig"}).

###### CAP1 expression in cancers

  Cancer              cancer subtype                              *p* −value   fold change   rank (%)   sample   reference
  ------------------- ------------------------------------------- ------------ ------------- ---------- -------- ------------
  **Bladder**         Infiltrating Bladder Urothelial Carcinoma   7.84E5       2.046         10         27       \[[@R25]\]
  **Breast**          Invasive Breast Carcinoma Stroma            9.62E--30    −15.461       2          59       \[[@R26]\]
  **Head and Neck**   Tongue Squamous Carcinoma                   1.68E--12    3.333         1          57       \[[@R27]\]
                      Tonsillar Carcinoma                         4.23E--5     2.1036        1          10       \[[@R28]\]
                      Tongue Carcinoma                            4.3E--7      2.439         2          19       \[[@R28]\]
                      Oropharyngeal Carcinoma                     7.91E--5     2.1           3          10       \[[@R28]\]
                      Tongue Squamous Carcinoma                   1.37E--11    3.095         2          57       \[[@R29]\]
  **Leukemia**        Chronic lymphocytic leukemia                9.13E--6     2.212         5          111      \[[@R30]\]
                      Acute myeloid leukemia                      3.79E--7     −5.989        1          31       \[[@R31]\]
                      T−cell acute lymphoblastic                  8.00E--9     −3.731        2          17       \[[@R32]\]
                      Acute myeloid leukemia                      2.59E--7     −2.198        5          144      \[[@R32]\]
                      T−cell acute lymphoblastic                  1.25E--7     −3.135        9          93       \[[@R32]\]
  **Lung**            Squamous cell lung Carcinoma                4.89E--13    3.2211        1          26       \[[@R29]\]
  **Lymphoma**        Anaplastic larger cell lymphoma             9.81E--5     2.140         1          27       \[[@R33]\]
                      Angioimmunoblastic T−cell lymphoma          9.82E--10    2.874         1          26       \[[@R33]\]
                      Unspecified peripheral T−cell lymphoma      2.79E--13    2.391         3          48       \[[@R33]\]
  **Melanoma**        Cutaneous Melanoma                          2.31E--5     3.629         8          52       \[[@R34]\]
  **Pancreatic**      Pancreatic carcinoma                        1.42E--5     4.732         1          17       \[[@R35]\]
                      Pancreatic adenocarcinoma                   5.83E--5     2.958         4          15       \[[@R36]\]
                      Pancreatic carcinoma                        6.86E--5     2.308         8          52       \[[@R37]\]
                      Pancreatic ductal adenocarcinoma            1.24E--9     2.520         5          78       \[[@R38]\]
  **Other**           Embryonal carcinoma                         1.16E--7     2.689         5          20       \[[@R39]\]
                      Seminoma, NOS                               5.64E--9     2.112         2          18       \[[@R39]\]
                      Teratoma, NOS                               1.60E--8     2.067         3          20       \[[@R39]\]

![CAP1 analysis in different cancer types (Oncomine database)\
The box plot comparing specific CAP1 expression in normal (left plot) and cancer tissue (right plot) was derived from Oncomine database. The fold change of CAP1 in various types of cancers was identified from our analyses in Table [1](#T1){ref-type="table"} and expressed as the forest plot (**A**). The analysis was shown in breast carcinoma relative to normal breast (**B**), in pancreatic carcinoma relative to normal pancreatic (**C**).](oncotarget-08-27216-g002){#F2}

Genetic alterations of CAP and overall survival (OS) {#s3_2}
----------------------------------------------------

Kaplan-Meier plotter analysis showed the relationship between the overexpression of CAP1 and overall high survival rates in lung cancer. Contrastingly, breast and ovarian cancers showed the relationship between overexpression of CAP1 and overall low survival rates ([Supplementary Figure 4](#SD1){ref-type="supplementary-material"}).

The prognostic value of CAP1 expression was reported by PrognoScan database (Figure [3](#F3){ref-type="fig"}, Table [4](#T4){ref-type="table"}). The poor prognosis in breast and ovarian cancer patients with higher CAP1 expression was in line with the data from Kaplan-Meier plotter analysis (Figure [4A, 4C](#F4){ref-type="fig"}, [Supplementary Figure 4](#SD1){ref-type="supplementary-material"}). The Oncomine, PrognoScan and Kaplan-Meier plotter data showed the oncogenic role of CAP1 in breast, ovarian, blood, and brain cancer; however that in lung cancer is not clear ([Supplementary Figure 4A, 4B](#SD1){ref-type="supplementary-material"}). Thus, to evaluate the oncogenic or tumor suppressor role of CAP1 in lung cancer, our previous study demonstrated that the protein expression was significantly higher in NSCLC tissues compared with their matched normal lung tissues. In addition, the expression of CAP1 in tumor tissues was significantly associated with a tumor, lymph node metastasis, and TNM stage in NSCLC patients; CAP1 was highly expressed in lung cancer with brain metastasis as compared to other metastatic groups (bone metastasis and visceral metastasis). Kaplan-Meier analysis showed that the OS rate in NSCLC patients with high CAP1 levels was significantly lower than that in those with low CAP1 levels \[[@R7], [@R40]\].

![CAP1 genes in different cancer types (PrognoScan database)\
The statistically significant hazard ratio in various types of cancers was identified from our analyses in Table [2](#T2){ref-type="table"} and expressed as the forest plot. The analysis of survival curve was identified as the threshold of cox *p*-value \< 0.05.](oncotarget-08-27216-g003){#F3}

###### The association of CAP1 expression and the survival in cancer patients

  Cancer type              *N*   COX *P*-VALUE   HR      ENDPOINT                           DATASET             PROBE ID
  ------------------------ ----- --------------- ------- ---------------------------------- ------------------- --------------
  Blood                    79    4.58 E--02      1.76    Overall Survival                   GSE12417-GPL570     213798_s\_at
                           79    3.46 E--02      1.83    Overall Survival                   GSE12417-GPL570     200625_s\_at
                           34    2.6 E--02       3.15    Overall Survival                   GSE8970             200625_s\_at
                           158   8.44 E--03      0.49    Overall Survival                   GSE4470             213798_s\_at
                           158   3.87 E--03      0.46    Overall Survival                   GSE4475             200625_s\_at
                           53    4.49 E--02      0.25    Overall Survival                   E-TABN-346          200625_s\_at
                           53    3.40 E--02      0.26    Overall Survival                   E-TABN-346          200625_s\_at
  **Brain**                50    1.05E--02       1.74    Overall Survival                   MGH-glioma          935_at
                           74    4.32E--02       2.96    Overall Survival                   GSE4412-GPL96       200625_s\_at
                           74    2.01E--02       3.42    Overall Survival                   GSE4412-GPL96       213798_s\_at
  **Breast**               115   4.68E--02       5.13    Distant Metastasis Free Survival   GSE19615            213798_s\_at
                           159   8.93E--03       1.78    Disease specific Survival          GSE1456-GPL96       213798_s\_at
                           159   1.94E--02       3.36    Relapse Free Survival              GSE1456-GPL96       200625_s\_at
                           159   2.07E--02       4.17    Disease specific Survival          GSE1456-GPL96       200625_s\_at
                           159   3.27E--02       2.23    Relapse Free Survival              GSE1456-GPL96       213798_s\_at
                           236   4.34E--02       2.9     Disease specific Survival          GSE1456-GPL96       200625_s\_at
                           236   1.40E--02       3.35    Disease specific Survival          GSE1456-GPL96       213798_s\_at
                           249   2.45E--02       2.39    Disease specific Survival          GSE1456-GPL96       213798_s\_at
                           249   2.13E--02       2.65    Disease specific Survival          GSE1456-GPL96       200625_s\_at
  **Colorectal**           55    8.98E--03       6.42    Disease free Survival              GSE17537            213798_s\_at
  **Lung**                 82    2.14E--03       0.31    Overall Survival                   Jacob-00182-CANDF   213798_s\_at
                           84    4.99E--02       2.45    Overall Survival                   HARVAD-LC           935_at
                           204   4.67E--05       29.59   Overall Survival                   GSE31210            213798_s\_at
                           204   1.21E--05       17.93   Relapse free Survival              GSE31210            213798_s\_at
                           204   6.9E--05        47.11   Overall Survival                   GSE31210            200625_s\_at
                           204   1E--05          34.9    Relapse free Survival              GSE31210            200625_s\_at
                           138   8.4E--05        2.23    Relapse free Survival              GSE8894             213798_s\_at
                           138   2.39E--03       1.94    Relapse free Survival              GSE8894             200625_s\_at
  **Overian**                                                                                                   
                           80    4.51E--02       2.92    Overall Survival                   GSE14764            200625_s\_at
                           80    2.02E--02       3.69    Overall Survival                   GSE14764            213798_s\_at
  **Soft tissue cancer**   140   2.22E--02       2.1     Distant Recurrence Free Survival   GSE130929           200625_s\_at
                           140   1.83E--02       2.09    Distant Recurrence Free Survival   GSE130929           213798_s\_at

###### CAP2 expression in cancers

  Cancer           cancer subtype                               *p*-value   fold change   rank (%)   sample   reference
  ---------------- -------------------------------------------- ----------- ------------- ---------- -------- ------------
  **Bladder**      Superficial Bladder cancer                   2E--15      −7.061        3          76       \[[@R41]\]
                   Superficial Bladder cancer                   2.79E--15   −2.41         4          194      \[[@R41]\]
                   Infiltrating Bladder Urothelial Carcinoma    9.95E--15   −4.549        5          129      \[[@R42]\]
  **Brain**        Glioblastoma                                 4.70E--17   −7.893        1          31       \[[@R43]\]
                   Brain Glioblastoma                           1.87E--22   −5.558        1          552      TCGA
                   Glioblastoma                                 8.42E--12   −3.522        2          25       \[[@R42]\]
                   Glioblastoma                                 2.90E--6    −4.275        3          84       \[[@R44]\]
                   Oligodendroglioma                            3.58E--7    −3.842        6          42       \[[@R45]\]
  **Breast**       Invasive Ductal Breast Carcinoma Epithelia   7.92E--6    2.074         1          23       \[[@R46]\]
  **Colorectal**   Colon Carcinoma                              5.13E--8    2.038         5          15       \[[@R47]\]
                   Colorectal Adenocarcinoma                    1.30E--6    −2.125        7          69       \[[@R47]\]
  **Esophageal**   Barrett\'s Esophagus                         7.38E--9    −2.728        8          43       \[[@R48]\]
                   Esophageal Adenocarcinoma                    1.26E--11   −2.124        9          103      \[[@R48]\]
  **Gastric**      Diffuse Gastric Adenocarcinoma               1.73E--5    4.120         1          37       \[[@R49]\]
                   Gastric Mixed Adenocarcinoma                 1.43E--6    3.077         2          35       \[[@R49]\]
  **Kidney**       Clear Cell Renal Cell Carcinoma              1.67E--6    3.098         5          31       \[[@R50]\]
                   Papillary Renal Cell Carcinoma               4.18E--5    2.459         3          5        \[[@R50]\]
  **Leukemia**     Pro-B Acute Lymphoblastic Leukemia           8.93E--16   2.209         8          144      \[[@R51]\]
  **Liver**        Hepatocellular Carcinoma                     3.27E--99   5.790         1          445      \[[@R52]\]
                   Hepatocellular Carcinoma                     2.26E--13   8.569         1          45       \[[@R53]\]
                   Liver Cell Dysplasia                         9.81E--5    2.140         1          27       \[[@R53]\]
                   Hepatocellular Carcinoma                     1.41E--28   3.526         1          179      \[[@R54]\]
                   Hepatocellular Carcinoma                     2.92E--10   4.254         1          43       \[[@R52]\]
  **Lung**         Squamous Cell Lung Carcinoma                 1.27E--6    −4.154        8          62       \[[@R29]\]
  **Melanoma**     Cutaneous Melanoma                           2.03E--9    3.743         3          52       \[[@R55]\]
                   Benign Melanocytic Skin Nevus                3.50E--5    −2.859        3          25       \[[@R55]\]
  **Ovarian**      Ovarian Serous Adenocarcinoma                1.44E--8    −3.384        7          53       \[[@R56]\]
  **Prostate**     Prostate Carcinoma                           5.86E--6    −2.238        2          34       \[[@R57]\]
  **sarcoma**      Myxofibrosarcoma                             5.56E--5    −3.711        10         40       \[[@R58]\]
  **Other**        Teratoma, NOS                                1.16E--7    2.689         5          20       \[[@R59]\]
                   Yolk Sac Tumor, NOS                          3.18E--6    2.342         4          15       \[[@R59]\]
                   Vulvar Intraepithelial Neoplasia             2.24E--6    −2.809        1          19       \[[@R60]\]

![CAP1 genes in Ovarian, Lung, Breast and Blood cancer types (PrognoScan database)\
The survival curve comparing the patient with high (red) and low (black) expression was plotted from PrognoScan database. The survival curve comparing the patient with high (red) and low (black) expression in ovarian cancer (**A**), lung cancer (**B**), breast cancer (**C**) and blood cancer (**D**) was plotted from PrognoScan database as the threshold of cox *p*-value \< 0.05.](oncotarget-08-27216-g004){#F4}

Furthermore, we used Oncomine to confirm the CAP2 expression in different types of cancers (Table [3](#T3){ref-type="table"}) \[[@R41]--[@R60]\]. CAP2 was upregulated in leukemia, gastric, breast, kidney, and liver cancer, whereas decreased in the bladder, brain, lung, prostate, oesophagus, and ovarian cancer, as well as sarcoma and melanoma (Figure [5A](#F5){ref-type="fig"}, [Supplementary Figures 5--7](#SD1){ref-type="supplementary-material"}). These data are in agreement with the previously published reports on CAP2 expression. For instance, CAP2 has been found to be overexpressed in hepatocellular carcinoma \[[@R8], [@R9]\] (Figure [5B](#F5){ref-type="fig"}).

![CAP2 analysis in different cancer types (Oncomine database)\
The box plot comparing specific CAP2 expression in normal (left plot) and cancer tissue (right plot) was derived from Oncomine database. The fold change of CAP2 in various types of cancers was identified from our analyses in Table [3](#T3){ref-type="table"} and expressed as the forest plot (**B**). The analysis was shown in Liver carcinoma relative to normal liver (**A**).](oncotarget-08-27216-g005){#F5}

We applied the Kaplan-Meier plotter to identify the OS of breast, ovarian, and gastric cancer patients. The results showed that CAP2 was associated with poor survival in gastric and ovarian cancers, but with better survival in breast cancer (Figures [6](#F6){ref-type="fig"}, [7](#F7){ref-type="fig"}). The prognostic value of CAP2 was reported by PrognoScan database (Figure [8C](#F8){ref-type="fig"}, Table [5](#T5){ref-type="table"}). The improved prognosis was observed in the brain, blood, and prostate cancer patients, whereas poor prognosis in the skin and colorectal cancers (Figure [8A--8B](#F8){ref-type="fig"}, [Supplementary Figure 8](#SD1){ref-type="supplementary-material"}).

![CAP2 genes in Breast, Ovarian and Gastric cancer (Kaplan-Meier Plotter)\
The survival curve comparing the patient with high (red) and low (black) expression in breast, ovarian and gastric cancer was plotted from Kaplan-Meier plotter database.](oncotarget-08-27216-g006){#F6}

![CAP2 genes in Lung cancer (PrognoScan database)\
The survival curve comparing the patient with high (red) and low (black) expression in lung cancer were plotted from PrognoScan database as the threshold of cox *p*-value \< 0.05.](oncotarget-08-27216-g007){#F7}

![CAP2 genes in Skin and Colon cancer (PrognoScan database)\
The survival curve comparing the patient with high (red) and low (black) expression in skin (**A**) and colon cancer (**B**) were plotted from PrognoScan database as the threshold of cox *p*-value \< 0.05. The statistically significant hazard ratio in various types of cancers was identified from our analyses in Table [4](#T4){ref-type="table"} and expressed as the forest plot (**C**).](oncotarget-08-27216-g008){#F8}

###### The association of CAP2 expression and the survival in cancer patients

  Cancer type      *N*   COX *P*-VALUE   HR     ENDPOINT                    DATASET           PROBE ID
  ---------------- ----- --------------- ------ --------------------------- ----------------- ----------------
  **Blood**                                                                                   
                   34    9.83 E--3       0.21   Overall survival            GSE8970           212551_at
                   158   6.49 E--3       0.2    Overall survival            GSE4475           212554_at
  **Brain**                                                                                   
                   67    4.07 E--2       0.31   Overall survival            GSE16581          HG-U133_plus_2
  **Breast**                                                                                  
                   159   8.04 E--3       0.57   Disease specific survival   GSE1456-GPL96     212554_at
                   159   1.13 E--2       0.55   Relapse free survival       GSE1456-GPL96     212551_at
                   159   4.23E--2        0.57   Disease specific survival   GSE1456-GPL96     212551_at
                   159   1.93 E--2       0.64   Relapse free survival       GSE1456-GPL96     212554_at
  **Colorectal**                                                                              
                   177   4.82 E--2       1.43   Overall survival            GSE17536          212551_at
                   177   8.16 E--3       1.47   Disease specific survival   GSE17536          212554_at
                   177   1.38 E--2       1.59   Disease specific survival   GSE17536          212551_at
                   177   3.08 E--2       1.35   Overall survival            GSE17536          212554_at
                   145   1.92 E--2       1.73   Relapse free survival       GSE17536          212554_at
                   226   3.21 E--3       1.74   Disease free survival       GSE14333          212554_at
                   55    3.61 E--2       1.82   Overall survival            GSE17537          212554_at
                   55    3.86 E--2       1.98   Disease free survival       GSE17537          212554_at
                   49    4.64 E--2       1.98   Disease specific survival   GSE17537          212554_at
  **lung**                                                                                    
                   104   1.46 E--2       0.47   Overall survival            Jacob-00182-MSK   212554_at
                   104   6.15 E--3       0.16   Overall survival            Jacob-00182-MSK   212554_at
                   117   3.69 E--2       1.43   Overall survival            GSE13213          A23P421664
                   204   4.64 E--4       0.4    Relapse free survival       GSE31210          212554_at
                   204   1.39 E--2       0.55   Relapse free survival       GSE31210          212551_at
  **Ovarian**                                                                                 
                   278   1.21E--2        1.38   Overall survival            GSE9891           212554_at
  **Prostate**                                                                                
                   281   4.58E--2        0.82   Overall survival            GSE16560          DAP4_2808
  **Skin**                                                                                    
                   38    2.15E--2        1.90   Overall survival            GSE19234          212554_at
                   38    3.32E--2        1.66   Overall survival            GSE19234          212554_at

Protein components of nodes across the CAP {#s3_3}
------------------------------------------

We selected the functional protein partners of CAP based on previous publications and curated databases. The ten predicted proteins of CAP1 (with the corresponding gene names) included: cofilin2 (*CFL2*), CAP2, slit homolog 2 (S*LIT2*), cofilin1 (*CFL1*), v-abl (*ABL2*), c-abl (*ABL1*), destrin (*DSTN*), ROBO1, profilin 1 (*PFN1*), and adenylate cyclase 1 brain (*ADCY1*) (Figure [9A](#F9){ref-type="fig"}). The ten predicted proteins of CAP2 (with the corresponding gene names) included: cofilin2 (*CFL2*), actin gamma1 (*ACTG1*), CAP1, actin beta (*ACTB*), slit homolog 2 (*SLIT2*), cofilin1 (*CFL1*), v-abl (*ABL2*), c-abl (*ABL1*), destrin (*DSTN*), and ROBO1 (Figure [9B](#F9){ref-type="fig"}).

![Identification of known and predicted structural proteins essential for CAP function\
Interacting nodes are displayed in colored circles using String, v10.0. Predicted functional partners of CAP1 (**A**) and CAP2 (**B**) are shown based upon peer reviewed published data and curated database entries. \[STRING v.10 (<http://string-db.org>).](oncotarget-08-27216-g009){#F9}

CAP homologs are comprised of three conserved structural domains, the N-terminal domain, the C-terminal domain, and a proline-rich central domain \[[@R61], [@R62]\]. All the three domains contribute to actin filament turnover through interactions with cofilin, and G- and F-actin \[[@R62]\]. In summary, CAP is a key actin-regulating protein that controls actin dynamics through multiple mechanisms including the cofilin-mediated depolymerization cycle \[[@R23]\]. Hence, we choose CAP2, CFL1, CFL2, and DSTN for further analysis of CAP1; CAP1, CFL1, CFL2, DSTN, ACTB, ACTG1 for further analysis of CAP2.

Unbiased cross cancer subtypes correlations by cBioPortal data {#s3_4}
--------------------------------------------------------------

Analyzing the five gene (CAP1) of mutations and CNAs by the cBioPortal tool with 91 different cancer studies. The results analyzed 5 different cancer studies representing 681 samples that contained \>20% alteration frequency and at least 100 samples in the dataset. The particular interest constituted the predominant pattern of amplification occurring in prostate cancer. CAP1 mutation mainly occurred in bladder cancer and existed in a hotspot in the CAP N domain (Figure [10A](#F10){ref-type="fig"}). Minor changes in the deletion or multiple alterations were observed in the results. The ratio of alteration ranged over 39.3--20.2% with the dominance hierarchy (highest to lowest) as prostate, ovarian, bladder, and pancreatic cancer (Figure [11A](#F11){ref-type="fig"}, Table [6](#T6){ref-type="table"}).

![Mutation diagram of CAP in different cancer types across protein domains\
CAP1 mutation frequencies are the highest in Bladder cancer. The 1 hot spots (R29CVS) represent the common founder mutations in CAP1 N-termial (**A**). CAP2 mutation frequencies are the highest in Myeloma cancer. CAP2 mutation occur in the N domain (**B**).](oncotarget-08-27216-g010){#F10}

![Copy number alteration of CAP genes and cancer subtypes\
(**A**) the alteration frequency of a five-gene signature (CAP2, CAP1, DSTN, CFL1 CFL2) was determined using the cBioPortal (<http://www.cbioportal.org>). (**B**) the alteration frequency of a seven-gene signature (CAP2, CAP1, DSTN, CFL1 CFL2, ACTB, ACTG1) was determined using the cBioPortal (<http://www.cbioportal.org>). Only cancer types containing \> 100 samples and an alteration frequency of \>20% are shown. The alteration frequency included deletions (blue), amplification (red), multiple alterations (grey) or mutation (green). The total number of samples for each cancer type are indicated by the numbers at the top of each column.](oncotarget-08-27216-g011){#F11}

###### The alteration frequency of a five-gene signature (CAP2, CAP1, DSTN, CFL1 CFL2) in cancers

  Cancer      Data source                 *N*   Frequency (%)   Amplification (%N)   Deletion (%N)   Mutation (%N)   Multiple alterations (%N)
  ----------- --------------------------- ----- --------------- -------------------- --------------- --------------- ---------------------------
  NEPC        Trento/Cornell/Broad 2016   107   39.3%           39.3% (42)                                           
  Ovarian     TCGA                        311   26%             25.42% (79)                          0.6% (2)        
  Bladder     TCGA 2014                   127   21.3%           14.2% (18)           1.6% (2)        4.7% (6)        0.8% (1)
  Bladder     TCGA                        127   29.9%           14.2% (18)           0.8% (1)        3.1% (4)        2.4% (3)
  Pancrease   UTSW                        109   20.2%           17.3% (19)           2.8% (3)                        

Further, we used the OncoPrint from a query for alterations in *CAP2*, *CAP1*, *CFL1*, *CFL2*, and *DSTN* genes. The percentages of alterations in these genes among prostate cancer varied from 13-30% for individual genes (*CAP2*, 19%; *CAP1*, 13%; *CFL1*, 30%; *CFL2*, 21%; *DSTN*, 19%) (Figure [12A](#F12){ref-type="fig"}, Table [7](#T7){ref-type="table"}); the *CFL1* gene was amplified predominantly in the prostate cancer type.

![Prostate cancer types frequently amplify CAP\
We used the Oncoprint feature of the cBioPortal (<http://www.cbioportal.org>) to determine the copy number alteration frequency of each individual gene in CAP within selected cancer subtypes. The percentages of alterations in *CAP2*, *CAP1*, *CFL1*, *CFL2*, and *DSTN* genes in the prostate cancer (**A**). The percentages of alterations in *CAP2*, *CAP1*, *CFL1*, *CFL2*, *DSTN*, *ACTB*, and *ACTG1* genes among prostate cancer (**B**). Grey bars along a vertical line represent the same sample interrogated for amplification (red), deep deletion (blue), missense mutation (green), truncating mutation (black) or in-frame mutation (brown).](oncotarget-08-27216-g012){#F12}

###### The percentages of alterations in CAP2, CAP1, CFL1, CFL2 and DSTN genes

  Cancer      CAP1   CAP2   CFL1   CFL2   DSTN
  ----------- ------ ------ ------ ------ ------
  NEPC        13%    19%    30%    21%    19%
  Ovarian     11%    12%    2.9%   1.3%   2.9%
  Bladder     11%    9%     2.4%   1.6%   0.8%
  Bladder     10%    9%     1.6%   1.6%   0.8%
  Pancrease   2.8%   4%     10%    5%     4%

The data showed 16 studies representing 4134 samples that contained \>20% alteration frequency and at least 100 samples of seven-gene (CAP2) query in the cBioPortal database. A thorough inspection displayed that this result represented approximately ten different cancer types. The predominant pattern of amplification occurring in prostate cancer was of particular interest. The evidence of CAP2 mutation was most predominant in uterine cancer. Also, minor changes in deletion or multiple alterations were observed in the results. Based on the context, it is presumed, that the Cap2 mutation occur in the N domain in the current sentence. (Figure [10B](#F10){ref-type="fig"}). The frequency of alteration ranged over 40.2--20% with the rank order (highest to lowest) as prostate, pancreatic, ovarian, bladder, and lung cancer followed by melanoma, oesophagus, uterine, and stomach cancer (Figure [11B](#F11){ref-type="fig"}, Table [8](#T8){ref-type="table"}).

###### The alteration frequency of a seven-gene signature (CAP2, CAP1, DSTN, CFL1 CFL2, ACTB, ACTG1) in cancers

  Cancer       Data source                 *N*   Frequency (%)   Amplification (%N)   Deletion (%N)   Mutation (%N)   Multiple alterations (%N)
  ------------ --------------------------- ----- --------------- -------------------- --------------- --------------- ---------------------------
  NEPC         Trento/Cornell/Broad 2016   107   40.2%           38.3% (41)                           0.9% (1)        0.9% (1)
  Pancrease    UTSW                        109   38.5%           31.2% (34)           4.6% (5)        1.8% (2)        0.9% (1)
  Ovarian      TCGA                        311   32.5%           28.3% (88)           2.9% (9)        1% (3)          0.3% (1)
  Bladder      TCGA 2014                   127   29.9%           16.5% (21)                           9.4% (12)       3.9% (5)
  Bladder      TCGA 127                    127   29.9%           17.3% (22)                           7.9% (10)       4.7% (6)
  CCLE         Novartis/ Broad 2012        881   24.1% (212)                                          4.1% (36)       
  Lung adeno   TCGA                        230   29.9% (44)      17.3% (10)                           7.9% (4)        4.7% (1)
  Melanoma     TCGA                        287   25.7%           19.1% (44)           4.3% (23)       0.4% (2)        1.7% (4)
  Lung adeno   TCGA pub                    230   25.4%           15.3%                0.7% ()         8% ()           1.4% ()
  Esophagus    TCGA                        184   25.2%           20.7% (38)           1.6% (3)        2.7% (5)        
  Ovarian      TCGA pub                    316   25%             19.9% (63)           0.9% (3)        1.3% (4)        
  Lung Squ     TCGA                        177   22%             14.1% (25)           1.7% (3)        5.6% (10)       0.6% (1)
  Uterine      TCGA                        242   21.9%           10.7% (26)           0.4 (1)         10.7 (26)       
  Stomach      TCGA pub                    287   21.6%           9.1% (26)            4.5% (13)       6.6% (19)       1.4% (4)
  Uterine      TCGA pub                    240   20%             8.8% (21)            0.4% (1)        10.8% (26)      

We also applied the OncoPrint database to explore the specific alterations in each gene. For example, percentages of alterations in *CAP2, CAP1*, *CFL1*, *CFL2*, *DSTN*, *ACTB*, and *ACTG1* genes among prostate cancer varied from 2.6--30% in individual genes (*CAP2*, 19%; *CAP1*, 13%; *CFL1*, 30%; *CFL2*, 21%; *DSTN*, 19%; *ACTG1*, 2.6%; *ACTB*, 21%;) (Figure [12B](#F12){ref-type="fig"}, Table [9](#T9){ref-type="table"}); the *CFL1* gene was amplified predominantly in prostate cancer. We also use Tumorscape database to verify the copy number changes in cancers. Figure [13](#F13){ref-type="fig"} shows the detail of CAP genomic regions that are either significantly amplified or deleted in specific cancer.

###### The percentages of alterations in CAP2, CAP1, CFL1, CFL2, DSTN, ACTB, and ACTG1 genes

  Cancer       ACTB   ACTG1   CAP1   CAP2   CFL1   CFL2   DSTN
  ------------ ------ ------- ------ ------ ------ ------ ------
  NEPC         21%    2.6%    13%    19%    30%    21%    19%
  Pancrease    17%    10%     2.8%   4%     10%    5%     4%
  Ovarian      4%     8%      11%    12%    2.9%   1.3%   2.9%
  Bladder      7%     6%      11%    9%     2.4%   1.6%   0.8%
  Bladder      8%     6%      10%    9%     1.6%   1.6%   0.8%
  CCLE         9%     6%      4%     4%     4%     5%     3%
  Lung adeno   8%     4%      1.7%   3%     0.4%   13%    1.7%
  Melanoma     7%     7%      1.4%   10%    4%     0.7%   1%
  Lung adeno   8%     4%      1.7%   3%     0%     12%    1.7%
  Esophagus    9%     3%      5%     2.2%   2.7%   2.7%   1.6%
  Ovarian      1.3%   4%      10%    7%     0.3%   1.3%   1.3%
  Lung Squ     2.3%   6%      3%     4%     1.1%   3%     4%
  Uterine      2.9%   6%      6%     7%     2.1%   2.9%   3%
  Stomach      8%     1.7%    3%     5%     1.4%   3%     3%
  Uterine      3%     6%      5%     7%     1.3%   3%     2.9%

![The interactions between CAP1 and CAP2 alteration (cBio Cancer Genomics Portal)\
Network view of the CAP1/CAP2 neighborhood in prostate cancer. CAP1 and CAP2 are seed genes (indicated with thick border), and all other genes are automatically identified as altered in prostate cancer. Darker red indicates increased frequency of alteration (defined by mutation, copy number amplification, or homozygous deletion) in prostate cancer.](oncotarget-08-27216-g013){#F13}

In order to find whether the identified correlation is significant for each gene pair, the portal performs a Fisher\'s exact test. The mutual exclusivity analysis showed that the events in the selected genes co-occur, and the pattern was statistically significant between CAP2 and CAP1, CFL1, CFL2, ACTB, DSTN, but not between CAP2 and ACTG1, the main reason for lower correlation between CAP2 and ACTG1 seems to be the lower mutation rate in ACTG1, as showed in Figure [12B](#F12){ref-type="fig"}, the percentage of alteration of ACTG1 gene is only 2.6% that is quite small compared with other genes (∼20%) in 107 samples. Functional plotting of the corresponding mRNA level associated with the genetic status of CAP1and CAP2 revealed that deletion of these two CAPs was associated with increased mRNA expression ([Supplementary Figure 9](#SD1){ref-type="supplementary-material"}).

The cBioPortal analysis program identified 12 types of human cancer with significant CNAs in the chosen genes' signature (CAP1, CAP2, CFL1, CFL2, DSTN). The CAP signature was created such as to represent the structures and functions of CAP. The CNAs of specific structural components of the CAP in tumors may be potential targets to prevent metastatic spread.

Furthermore, we analyzed the interactions between CAP1 and CAP2 alteration via computation to reveal a moderate strength of direct interaction (Figure [13](#F13){ref-type="fig"}).

The co-expression of CAP were analyzed by Oncomine (Figures [14](#F14){ref-type="fig"}, [15](#F15){ref-type="fig"}, [Supplementary Figures 10, 11](#SD1){ref-type="supplementary-material"}). The co-expression profile of CAP1 was identified with a big cluster of 127 genes across 39 pancreatic carcinomas and 39 normal pancreatic tissues (Figure [14](#F14){ref-type="fig"}), as well as 52 genes across 32 head-neck and 26 normal samples ([Supplementary Figure 10](#SD1){ref-type="supplementary-material"}). CAP1 was co-expressed with Tubulin alpha-1B chain (*TUBA1B*) in both pancreatic and head-neck cancer. TUBA1B expression has been reported to be unregulated in liver tumor tissues, and an increased TUBA1B expression was associated with poor overall survival and resistance to paclitaxel in liver cancer patients \[[@R63]\].

![CAP1 genes in Pancreatic cancer\
CAP1 is coexpressed with the indicated genes across a panel of 39 pancreatic and 39 normal samples. Bar length represented the significance and negative logarithm of enrichment *p*-value.](oncotarget-08-27216-g014){#F14}

![CAP2genes in Liver cancer\
CAP1 is coexpressed with the indicated genes across a panel of 225 Liver and 220 normal samples. Bar length represented the significance and negative logarithm of enrichment *p*-value.](oncotarget-08-27216-g015){#F15}

In addition, we explored the co-expression profiles for CAP2 with 20 genes across 225 liver carcinomas and 220 normal liver tissues (Figure [15](#F15){ref-type="fig"}), and 20 genes across 157 brain and 23 normal samples. Additionally, 17 genes across 89 prostate cancers and 23 normal prostate tissues were also discovered ([Supplementary Figure 11](#SD1){ref-type="supplementary-material"}). Interestingly, CAP2 was coexpressed with tumor protein p53 binding protein 2 (*TP53BP2*) and ENA/VASP expressed in liver cancer. TP53BP2 was associated with several types of cancers. \[[@R63]\]. TP53BP2 is a key regulator of epithelial plasticity that connects cell polarity to suppress tumor metastasis \[[@R64]\]. Overexpression of TP53BP2 promoted the proliferation in breast cancer cells \[[@R65], [@R66]\]. On the other hand, ENA/VASP proteins are actin-associated proteins implicated in series of processes rely on cytoskeleton remodeling and cell polarities, such as axon guidance and lamellipodia and filopodia dynamics in migrating cells \[[@R67]--[@R69]\]. The GO analyses demonstrated the potential pathway of CAP1 and CAP2 by ICGC ([Supplementary Figure 12](#SD1){ref-type="supplementary-material"}) \[[@R70], [@R71]\]. CAP is involved in actin binding, cell morphogenesis, and cell migration. The precise underlying mechanism through which CAP1 and CAP2 modulate cancer progression need to be further studied.

DISCUSSION {#s4}
==========

CAP has been proved to prompt tumor development in cancers \[[@R7]--[@R10]\]. Despite scores of CAPs identified so far, little is known whether they can serve as markers for cancer diagnosis/prognosis. In order to establish the compelling evidence, in the present study, we conducted the data depend on plenty of genes expression with clearly defined parameters between cancer and normal tissues. In the Oncomine analysis, CAP1 was found to be unregulated in various cancer types (Table [1](#T1){ref-type="table"}, Figure [1](#F1){ref-type="fig"}), but deregulated in leukemia and breast cancer. CAP2 was deregulated in various cancer types (Table [3](#T3){ref-type="table"}, Figure [1](#F1){ref-type="fig"}), but unregulated in liver, gastric, kidney, and breast cancer.

To further explore the OS between CAP and various types of cancer, the correlations between CAP gene and survival rates was evaluated using the Kaplan-Meier Plotter and PrognoScan. Overall, high levels of CAP1 gene expression result in low survival in breast and ovarian cancers (Table [2](#T2){ref-type="table"}). However, the results between OS and lung cancer is not clear. Our previous study confirmed the role of CAP1 in lung cancer demonstrated that the expression of CAP1 was significantly higher in NSCLC tissues as compared to the corresponding normal lung tissues. Moreover, CAP2 gene expression led to increased survival.

Somatically acquired genetic, epigenetic, transcriptomic, and proteomic alterations are the main four causes of cancer cells \[[@R72]\]. These alterations occur in specific genomic regions, which could show their potential suppressive or oncogenic roles \[[@R73]\]. Thus, the cBioPortal analysis to identify human cancers discovered significant CNA in the chosen CAP-gene signature. The present study focused on a specific group of CAP from HGNC to examine the prostate cancer dataset (provisional) on the cBioPortal. The cBioPortal analysis found that the frequency of 40.2--20% with the rank order mainly in prostate cancer with CAP1 and CAP2 alteration ranged from 38.3--19.8%. The CAP mutations occurs in the N domain of CAP (Figures [11](#F11){ref-type="fig"}, [12](#F12){ref-type="fig"}).

The cBioPortal can be used for interactive analysis and visualization of altered networks. The networks consist of pathways and interactions from the Human Protein Reference Database \[[@R74]\], Reactome \[[@R75]\], NCI Pathway Interaction Database \[[@R76]\], and the MSKCC Cancer Cell Map \[[@R77]\]. Figure [13](#F13){ref-type="fig"} showed that the Network view of the CAP1/CAP2 neighborhood in prostate cancer, those results its better to understand the molecular mechanisms of CAP underlying cancer.

The Oncomine™ database displays a potentially significant list of coexpressed genes, which is critical in defining pathways. Co-expression analysis revealed that CAP1 was coexpressed with TUBA1B both in pancreatic and head-neck cancer (Figure [14](#F14){ref-type="fig"}), as well as with CFL1, CFL2, DSTN, and ROBO1, according to STRING analysis. CAP2 was coexpressed with TP53BP2, ENA/VASP in the liver cancer (Figure [15](#F15){ref-type="fig"}), and CFL1, CFL2, DSTN, ACTB, ACTG1, and ROBO1. In addition, our previous studies found that CAP1 was overexpressed in NSCLC tissues and correlated with poor clinical outcomes \[[@R7]\]. In order to clarify the molecular mechanisms of CAP1 on the metastasis of NSCLC cells, our previous studies showed that CAP1 was a phosphorylatable protein. Zhou et al. found that homologs of CAP1 had four phosphorylation sites: S36, S307, S309, and T314. CAP1 regulates cancer mechanism through Tandem phosphorylation of S307 and S309 and association with cofilin and actin by GSK3 in HeLa cells \[[@R24]\]. Zhang et al. also found that CAP1 promotes breast cancer cell proliferation and metastasis mediated by ERK \[[@R78]\]. These mechanistic insights may ultimately lead to therapeutic strategies targeting CAP1 or its peripheral cell signals in cancer treatment.

As is known to all, this is the first study indicating the function of CAP members in cancer development. The present study facilitated access and interpretation of multidimensional oncogenic data. The use of the portals contributes to a better understanding of cancer molecular etiology and epidemiology that will ultimately accelerate the translation of genomic knowledge into clinical practice \[[@R79]\]. The current study aimed to show extensive oncogenic databases for the better understanding of the molecular mechanisms. In addition, we show an explicit direction through several web-based oncogenic portals that were established to facilitate researchers from different cancer-associated fields. Descriptions of the specific portals prepared on the basis of their versions from 2016 were summarized in Table [5](#T5){ref-type="table"}.

MATERIALS AND METHODS {#s5}
=====================

Oncomine database analysis {#s5_1}
--------------------------

The expression level of CAP gene in various types of cancers was identified from Oncomine database (<https://www.oncomine.org/resource/login.html>) \[[@R13], [@R14]\]. The mRNA expression fold in cancer tissue compared to the normal tissue was obtained as the parameters of *p*-value \< 1E-4, fold change \> 2, and gene ranking in the top 10% and the analyses were summarized in Tables [1](#T1){ref-type="table"}, [3](#T3){ref-type="table"}. The co-expression profiles of CAP gene in different types of cancers were identified and presented as the pattern of heat map.

Kaplan-Meier plotter database analysis {#s5_2}
--------------------------------------

The Kaplan Meier plotter is capable to assess the effect of 54,675 genes on survival using 10,188 cancer samples (4,142 breast, 1,648 ovarian, 2,437 lungs and 1,065 gastric cancer) on the HGU133 Plus 2.0 array. The correlation between CAP expression and survival in breast, gastric, ovarian and lung was analyzed by Kaplan-Meier plotter (<http://kmplot.com/analysis/>) \[[@R15]\]. The hazard ratio with 95% confidence intervals and log rank *p*-value was also computed.

Prognoscan database analysis {#s5_3}
----------------------------

The correlation between CAP expression and survival in various types of cancers was analyzed by PrognoScan database (<http://www.abren.net/PrognoScan/>) \[[@R16]\]. The threshold was adjusted to cox *p*-value \< 0.05 and the analyses were summarized in Tables [2](#T2){ref-type="table"}, [4](#T4){ref-type="table"}.

Identifying the protein components of CAP axis {#s5_4}
----------------------------------------------

The STRING analysis tool was used to determine interacting proteins using CAP as the query (<http://string-db.org>). The adenylate cyclase-associated protein (Homo saplens) was used. Several known partners have been genetically verified and therefore served as the foundation for finding the other protein partners in the axis. Any proteins identified that were not specific to the CAP axis, (e.g., slit homolog 2 \[SLIT2\]) were excluded from the gene signature \[[@R17], [@R18]\].

cBioPortal database analysis {#s5_5}
----------------------------

We utilized the ability to conduct an integrative analysis of CAP gene and clinical characteristic using the cBioPortal data, an open access resource at <http://www.cbioportal.org/> \[[@R19], [@R20]\], currently provided access to data from more than 5,000 tumor samples from 105 cancer studies in the TCGA pipeline. The query interface combined with customized data storage enabled us to interactively explore genetic alterations across samples curated from national and international cancer studies and specific genes. The primary search parameters included alterations (amplification, deep deletion, missense mutations), CNA from GISTIC and RNA seq data with the default setting. For the secondary search, we focused on RNA seq data.

Tumorscape database analysis {#s5_6}
----------------------------

Tumorscape \[[@R21], [@R22]\] was developed at The Broad Institute of MIT and Harvard in Cambridge, MA USA (<http://www.broadinstitute.org/tumorscape/>). This website was one of the first oncogenomic portals to provide information about cancer copy number changes in a format that was easily accessible to non- bioinformaticians. With this portal, the copy number profiles of over 3,700 cancers (both primary cancers and cell lines) are mapped to the human genome reference sequence and are visualized as heatmap tracks, with the use of the Integrative Genomics Viewer (The Broad Institute). Genomic regions with increased (\> 2) and decreased (\< 2) copy number are marked, respectively, in red and blue colors, the intensity of which indicates the amplitude of the copy number changes. The tracks that represent all of the analyzed samples are shown next to one another, forming a panel that allows direct comparison and visualization of all of the analyzed samples. In addition, Tumorscape provides tools that allow "cancer-centric" and "gene-centric" data analyses.

Statistical analysis {#s5_7}
--------------------

The results were performed using GraphPad Prism version 6 (GraphPad Software, La Jolla, CA, USA). Survival curves generated by the cBioPortal and Kaplan-Meier plots. All results are displayed with *P* values from a log-rank test. Similarly, with Oncomine, heat maps. Statistical significance of the data (*P*-values) was provided by the program.

CONCLUSIONS {#s6}
===========

In summary, bioinformatics analyses with Kaplan-Meier plotter, PrognoScan, cBioPortal, STRING analysis, Oncomine, Tumorscape, and ICGC Data Portal indicates that CAP is implicated in the cancer progressive. The inhibitor or activator of CAP for cancer treatment is based on different cancer types. Furthermore, by learning the databases of this study, researchers can explore the signaling network of CAP in cancer or other diseases.
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CAP

:   adenylate cyclase-associated protein

NSCLC

:   non-small cell lung cancer

CNA

:   copy number alteration

ICGC

:   International Cancer Genome Consortium

CFL1

:   cofilin1

CFL2

:   cofilin2

DSTN

:   destrin; ROBO1

TUBA1B

:   Tubulin alpha-1B chain

TP53BP2

:   tumor protein p53 binding protein, 2

ENA/VASP

:   ACTB, actin, beta

ACTG1

:   actin, gamma1

v-abl

:   ABL2

c-abl

:   ABL1
